Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis.
Ahmed AlTurkiMariam MarafiAhmed DawasJacqueline JozaRiccardo ProiettiVincenzo RussoThomas MavrakanasEmilie TrinhCatherine WeberRita SuriVidal EssebagThao HuynhPublished in: Journal of arrhythmia (2024)
Apixaban was associated with superior outcomes and reduced adverse events compared to warfarin in observational studies of patients with atrial fibrillation on dialysis. Randomized controlled studies are needed to confirm these findings.
Keyphrases
- end stage renal disease
- chronic kidney disease
- atrial fibrillation
- venous thromboembolism
- peritoneal dialysis
- systematic review
- case control
- direct oral anticoagulants
- double blind
- open label
- meta analyses
- oral anticoagulants
- placebo controlled
- phase iii
- randomized controlled trial
- clinical trial
- metabolic syndrome
- type diabetes
- insulin resistance
- glycemic control